Copyright © 2013 Kowichi Jimbow et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. E. de Vries, L. V. van de Poll-Franse, W. J. Louwman, F. R. de Gruijl, and J. W. W. Coebergh, “Predictions of skin cancer incidence in the Netherlands up to 2015,” The British Journal of Dermatology, vol. 152, no. 3, pp. 481–488, 2005. View at Publisher · View at Google Scholar · View at Scopus
2. C. M. Balch, J. E. Gershenwald, S. J. Soong et al., “Final version of 2009 AJCC melanoma staging and classification,” Journal of Clinical Oncology, vol. 27, no. 36, pp. 6199–6206, 2009. View at Publisher · View at Google Scholar · View at Scopus
3. C. M. Balch, A. C. Buzaid, S. J. Soong et al., “Final version of the American joint committee on cancer staging system for cutaneous melanoma,” Journal of Clinical Oncology, vol. 19, no. 16, pp. 3635–3648, 2001. View at Scopus
4. K. Reszka and K. Jimbow, “Electron donor and acceptor properties of melanin pigments in the skin,” in Oxidative Stress in Dermatology, J. Fuchs and L. Packer, Eds., pp. 287–320, Marcel Dekker, New York, NY, USA, 1993.
5. K. Jimbow, T. Iwashina, F. Alena, K. Yamada, J. Pankovich, and T. Umemura, “Exploitation of pigment biosynthesis pathway as a selective chemotherapeutic approach for malignant melanoma,” Journal of Investigative Dermatology, vol. 100, no. 2, pp. s231–s238, 1993. View at Scopus
6. F. Alena, T. Iwashina, A. Gili, and K. Jimbow, “Selective in vivo accumulation of N-acetyl-4-S-cysteaminylphenol in B16F10 murine melanoma and enhancement of its in vitro and in vivo antimelanoma effect by combination of buthionine sulfoximine,” Cancer Research, vol. 54, no. 10, pp. 2661–2666, 1994. View at Scopus
7. J. M. Pankovich and K. Jimbow, “Tyrosine transport in a human melanoma cell line as a basis for selective transport of cytotoxic analogues,” Biochemical Journal, vol. 280, no. 3, pp. 721–725, 1991. View at Scopus
8. M. Tandon, P. D. Thomas, M. Shokravi et al., “Synthesis and antitumour effect of the melanogenesis-based antimelanoma agent N-Propionyl-4-S-cysteaminylphenol,” Biochemical Pharmacology, vol. 55, no. 12, pp. 2023–2029, 1998. View at Publisher · View at Google Scholar · View at Scopus
9. A. Gili, P. D. Thomas, M. Ota, and K. Jimbow, “Comparison of in vitro cytotoxicity of N-acetyl and N-propionyl derivatives of phenolic thioether amines in melanoma and neuroblastoma cells and the relationship to tyrosinase and tyrosine hydroxylase enzyme activity,” Melanoma Research, vol. 10, no. 1, pp. 9–15, 2000. View at Scopus
10. P. D. Thomas, H. Kishi, H. Cao et al., “Selective incorporation and specific cytocidal effect as the cellular basis for the antimelanoma action of sulphur containing tyrosine analogs,” Journal of Investigative Dermatology, vol. 113, no. 6, pp. 928–934, 1999. View at Publisher · View at Google Scholar · View at Scopus
11. A. Ito, M. Shinkai, H. Honda, and T. Kobayashi, “Medical application of functionalized magnetic nanoparticles,” Journal of Bioscience and Bioengineering, vol. 100, no. 1, pp. 1–11, 2005. View at Publisher · View at Google Scholar · View at Scopus
12. N. Kawai, A. Ito, Y. Nakahara et al., “Anticancer effect of hyperthermia on prostate cancer mediated by magnetite cationic liposomes and immune-response induction in transplanted syngeneic rats,” Prostate, vol. 64, no. 4, pp. 373–381, 2005. View at Publisher · View at Google Scholar · View at Scopus
13. M. Shinkai, M. Yanase, H. Honda, T. Wakabayashi, J. Yoshida, and T. Kobayashi, “Intracellular hyperthermia for cancer using magnetite cationic liposomes: in vitro study,” Japanese Journal of Cancer Research, vol. 87, no. 11, pp. 1179–1183, 1996. View at Scopus
14. A. Ménoret and R. Chandawarkar, “Heat-shock protein-based anticancer immunotherapy: an idea whose time has come,” Seminars in Oncology, vol. 25, no. 6, pp. 654–660, 1998. View at Scopus
15. P. K. Srivastava, A. Ménoret, S. Basu, R. Binder, and K. Quade, “Heat shock proteins come of age: primitive functions acquired new roles in an adaptive world,” Immunity, vol. 8, no. 6, pp. 657–665, 1998. View at Publisher · View at Google Scholar
16. Y. Tamura, N. Tsuboi, N. Sato, and K. Kikuchi, “70 kDa heat shock cognate protein is a transformation-associated antigen and a possible target for the host's anti-tumor immunity,” Journal of Immunology, vol. 151, no. 10, pp. 5516–5524, 1993. View at Scopus
17. Y. Tamura, P. Peng, K. Liu, M. Daou, and P. K. Srivastava, “Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations,” Science, vol. 278, no. 5335, pp. 117–120, 1997. View at Publisher · View at Google Scholar · View at Scopus
18. Y. Tamura and N. Sato, “Heat shock proteins: chaperoning of innate and adaptive immunities,” Japanese Journal of Hyperthermic Oncology, vol. 19, pp. 131–139, 2003.
19. P. K. Srivastava, “Immunotherapy for human cancer using heat shock protein-peptide complexes,” Current Oncology Reports, vol. 7, no. 2, pp. 104–108, 2005. View at Publisher · View at Google Scholar
20. Y. Tamura, S. Takashima, J. M. Cho et al., “Inhibition of natural killer cell cytotoxicity by cell growth-related molecules,” Japanese Journal of Cancer Research, vol. 87, no. 6, pp. 623–630, 1996. View at Scopus
21. G. Ueda, Y. Tamura, I. Hirai et al., “Tumor-derived heat shock protein 70-pulsed dendritic cells elicit-tumor-specific cytotoxic T lymphocytes (CTLs) and tumor immunity,” Cancer Science, vol. 95, no. 3, pp. 248–253, 2004. View at Publisher · View at Google Scholar · View at Scopus
22. A. Ito, H. Honda, and T. Kobayashi, “Cancer immunotherapy based on intracellular hyperthermia using magnetite nanoparticles: a novel concept of “heat-controlled necrosis” with heat shock protein expression,” Cancer Immunology, Immunotherapy, vol. 55, no. 3, pp. 320–328, 2006. View at Publisher · View at Google Scholar · View at Scopus
23. H. Shi, T. Cao, J. E. Connolly et al., “Hyperthermia enhances CTL cross-priming,” Journal of Immunology, vol. 176, no. 4, pp. 2134–2141, 2006. View at Scopus
24. J. Dakour, T. Vinayagamoorthy, K. Jimbow et al., “Identification of a cDNA coding for a Ca²⁺-binding phosphoprotein (p90) calnexin, on melanosomes in normal and malignant human melanocytes,” Experimental Cell Research, vol. 209, no. 2, pp. 288–300, 1993. View at Publisher · View at Google Scholar · View at Scopus
25. K. Toyofuku, I. Wada, K. Hirosaki, J. S. Park, Y. Hori, and K. Jimbow, “Promotion of tyrosinase folding in Cos 7 cells by calnexin,” Journal of Biochemistry, vol. 125, no. 1, pp. 82–89, 1999. View at Scopus
26. K. Jimbow, P. F. Gomez, K. Toyofuku et al., “Biological role of tyrosinase related protein and its biosynthesis and transport from TGN to stage I melanosome, late endosome, through gene transfection study,” Pigment Cell Research, vol. 10, no. 4, pp. 206–213, 1997. View at Scopus
27. K. Jimbow, J. S. Park, F. Kato et al., “Assembly, target-signaling and intracellular transport of tyrosinase gene family proteins in the initial stage of melanosome biogenesis,” Pigment Cell Research, vol. 13, no. 4, pp. 222–229, 2000. View at Publisher · View at Google Scholar · View at Scopus
28. K. Jimbow, C. Hua, P. F. Gomez et al., “Intracellular vesicular trafficking of tyrosinase gene family protein in Eu- and pheomelanosome biogenesis,” Pigment Cell Research, vol. 13, no. 8, pp. 110–117, 2000. View at Scopus
29. T. Miura, K. Jimbow, and S. Ito, “The in vivo antimelanoma effect of 4-S-cysteaminylphenol and its N-acetyl derivative,” International Journal of Cancer, vol. 46, no. 5, pp. 931–934, 1990. View at Publisher · View at Google Scholar · View at Scopus
30. S. Ito, T. Kato, K. Ishikawa, T. Kasuga, and K. Jimbow, “Mechanism of selective toxicity of 4-S-cysteinylphenol and 4-S-cysteaminylphenol to melanocytes,” Biochemical Pharmacology, vol. 36, no. 12, pp. 2007–2011, 1987. View at Scopus
31. Y. Minamitsuji, K. Toyofuku, S. Sugiyama, K. Yamada, and K. Jimbow, “Sulfur containing tyrosine analogs can cause selective melanocytotoxicity involving tyrosinase-mediated apoptosis,” Journal of Investigative Dermatology Symposium Proceedings, vol. 4, no. 2, pp. 130–136, 1999. View at Scopus
32. K. Jimbow, Y. Miyake, K. Homma et al., “Characterization of melanogenesis and morphogenesis of melanosomes by physicochemical properties of melanin and melanosomes in malignant melanoma,” Cancer Research, vol. 44, no. 3, pp. 1128–1134, 1984. View at Scopus
33. B. Thiesen and A. Jordan, “Clinical applications of magnetic nanoparticles for hyperthermia,” International Journal of Hyperthermia, vol. 24, no. 6, pp. 467–474, 2008. View at Publisher · View at Google Scholar · View at Scopus
34. M. Johannsen, U. Gneveckow, L. Eckelt et al., “Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique,” International Journal of Hyperthermia, vol. 21, no. 7, pp. 637–647, 2005. View at Publisher · View at Google Scholar · View at Scopus
35. A. Ito, M. Fujioka, T. Yoshida et al., “4-S-Cysteaminylphenol-loaded magnetite cationic liposomes for combination therapy of hyperthermia with chemotherapy against malignant melanoma,” Cancer Science, vol. 98, no. 3, pp. 424–430, 2007. View at Publisher · View at Google Scholar · View at Scopus
36. M. Sato, T. Yamashita, M. Ohkura et al., “N-propionyl-cysteaminylphenol-magnetite conjugate (NPrCAP/M) Is a nanoparticle for the targeted growth suppression of melanoma cells,” Journal of Investigative Dermatology, vol. 129, no. 9, pp. 2233–2241, 2009. View at Publisher · View at Google Scholar · View at Scopus
37. T. Takada, T. Yamashita, M. Sato et al., “Growth inhibition of re-challenge B16 melanoma transplant by conjugates of melanogenesis substrate and magnetite nanoparticles as the basis for developing melanoma-targeted chemo-thermo-immunotherapy,” Journal of Biomedicine and Biotechnology, vol. 2009, Article ID 457936, 13 pages, 2009. View at Publisher · View at Google Scholar · View at Scopus
38. M. Suzuki, M. Shinkai, H. Honda, and T. Kobayashi, “Anticancer effect and immune induction by hyperthermia of malignant melanoma using magnetite cationic liposomes,” Melanoma Research, vol. 13, no. 2, pp. 129–135, 2003. View at Publisher · View at Google Scholar · View at Scopus
39. M. Yanase, M. Shinkai, H. Honda, T. Wakabayashi, J. Yoshida, and T. Kobayashi, “Intracellular hyperthermia for cancer using magnetite cationic liposomes: an in vivo study,” Japanese Journal of Cancer Research, vol. 89, no. 4, pp. 463–469, 1998. View at Scopus
40. R. Hergt, S. Dutz, R. Müller, and M. Zeisberger, “Magnetic particle hyperthermia: nanoparticle magnetism and materials development for cancer therapy,” Journal of Physics Condensed Matter, vol. 18, no. 38, pp. S2919–S2934, 2006. View at Publisher · View at Google Scholar · View at Scopus
41. A. Ito, M. Shinkai, H. Honda et al., “Heat shock protein 70 expression induces antitumor immunity during intracellular hyperthermia using magnetite nanoparticles,” Cancer Immunology, Immunotherapy, vol. 52, no. 2, pp. 80–88, 2003. View at Scopus
42. A. Ito, F. Matsuoka, H. Honda, and T. Kobayashi, “Antitumor effects of combined therapy of recombinant heat shock protein 70 and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma,” Cancer Immunology, Immunotherapy, vol. 53, no. 1, pp. 26–32, 2004. View at Publisher · View at Google Scholar · View at Scopus
43. A. Sato, Y. Tamura, N. Sato et al., “Melanoma-targeted chemo-thermo-immuno (CTI)-therapy using N-propionyl-4-S-cysteaminylphenol-magnetite nanoparticles elicits CTL response via heat shock protein-peptide complex release,” Cancer Science, vol. 101, no. 9, pp. 1939–1946, 2010. View at Publisher · View at Google Scholar · View at Scopus
44. P. Manini, A. Napolitano, W. Westerhof, P. A. Riley, and M. D'Ischia, “A reactive ortho-quinone generated by tyrosinase-catalyzed oxidation of the skin depigmenting agent monobenzone: self-coupling and thiol-conjugation reactions and possible implications for melanocyte toxicity,” Chemical Research in Toxicology, vol. 22, no. 8, pp. 1398–1405, 2009. View at Publisher · View at Google Scholar · View at Scopus
45. A. Ito, M. Yamaguchi, N. Okamoto et al., “T-cell receptor repertoires of tumor-infiltrating lymphocytes after hyperthermia using functionalized magnetite nanoparticles,” Nanomedicine, 2012. View at Publisher · View at Google Scholar
46. Y. Ishii-Osai, T. Yamashita, Y. Tamura et al., “N-Propionyl-4-S-cysteaminylphenol induces apoptosis in B16F1 cells and mediates tumor-specific T-cell immune responses in a mouse melanoma model,” Journal of Dermatological Science, vol. 67, no. 1, pp. 51–60, 2012. View at Publisher · View at Google Scholar
47. S. Ito, A. Nishigaki, Y. Ishii-Osai et al., “Mechanism of putative neo-antigen formation from N-propionyl-4-S-cysteaminylphenol, a tyrosinase substrate, in melanoma models,” Biochemical Pharmacology, vol. 84, no. 5, pp. 646–653, 2012. View at Publisher · View at Google Scholar
48. K. Jimbow, H. Obata, M. A. Pathak, and T. B. Fitzpatrick, “Mechanism of depigmentation by hydroquinone,” Journal of Investigative Dermatology, vol. 62, no. 4, pp. 436–449, 1974. View at Scopus
49. J. J. Nordlund, B. Forget, J. Kirkwood, and A. B. Lerner, “Dermatitis produced by applications of monobenzone in patients with active vitiligo,” Archives of Dermatology, vol. 121, no. 9, pp. 1141–1144, 1985. View at Publisher · View at Google Scholar · View at Scopus
50. R. E. Boissy and P. Manga, “On the etiology of contact/occupational vitiligo,” Pigment Cell Research, vol. 17, no. 3, pp. 208–214, 2004. View at Publisher · View at Google Scholar · View at Scopus
51. C. J. Cooksey, K. Jimbow, E. J. Land, and P. A. Riley, “Reactivity of orthoquinones involved in tyrosinase-dependent cytotoxicity: differences between alkylthio- and alkoxy-substituents,” Melanoma Research, vol. 2, no. 5-6, pp. 283–293, 1993. View at Scopus
52. P. G. Parsons, D. Favier, M. McEwan, H. Takahashi, K. Jimbow, and S. Ito, “Action of cysteaminylphenols on human melanoma cells in vivo and in vitro: 4-S-cysteaminylphenol binds protein disulphide isomerase,” Melanoma research, vol. 1, no. 2, pp. 97–104, 1991. View at Scopus
53. V. Hariharan, J. Klarquist, M. J. Reust et al., “Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: relevance to skin depigmentation,” Journal of Investigative Dermatology, vol. 130, no. 1, pp. 211–220, 2010. View at Publisher · View at Google Scholar · View at Scopus
54. J. G. van den Boorn, D. I. Picavet, P. F. van Swieten et al., “Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy,” Journal of Investigative Dermatology, vol. 131, no. 6, pp. 1240–1251, 2011. View at Publisher · View at Google Scholar · View at Scopus
55. J. G. van den Boorn, D. Konijnenberg, E. P. Tjin et al., “Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG,” PloS ONE, vol. 5, no. 5, Article ID e10626, 2010. View at Publisher · View at Google Scholar · View at Scopus
56. P. Quaglino, F. Marenco, S. Osella-Abate et al., “Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study,” Annals of Oncology, vol. 21, no. 2, pp. 409–414, 2010. View at Publisher · View at Google Scholar · View at Scopus
57. W. Westerhof, P. Manini, A. Napolitano, and M. d'Ischia, “The haptenation theory of vitiligo and melanoma rejection: a close-up,” Experimental Dermatology, vol. 20, no. 2, pp. 92–96, 2011. View at Publisher · View at Google Scholar
58. J. G. van den Boorn, C. J. Melief, and R. M. Luiten, “Monobenzone-induced depigmentation: from enzymatic blockage to autoimmunity,” Pigment Cell and Melanoma Research, vol. 24, no. 4, pp. 673–679, 2011. View at Publisher · View at Google Scholar
59. W. Westerhof and M. D'Ischia, “Vitiligo puzzle: the pieces fall in place,” Pigment Cell Research, vol. 20, no. 5, pp. 345–359, 2007. View at Publisher · View at Google Scholar · View at Scopus
60. T. Kato, S. Ito, and K. Fujita, “Tyrosinase-catalyzed binding of 3,4-dihydroxyphenylalanine with proteins through the sulfhydryl group,” Biochimica et Biophysica Acta, vol. 881, no. 3, pp. 415–421, 1986. View at Scopus
61. S. Ito, T. Kato, and K. Fujita, “Covalent binding of catechols to proteins through the sulphydryl group,” Biochemical Pharmacology, vol. 37, no. 9, pp. 1707–1710, 1988. View at Publisher · View at Google Scholar · View at Scopus
62. F. Alena, K. Jimbow, and S. Ito, “Melanocytotoxicity and antimelanoma effects of phenolic amine compounds in mice in vivo,” Cancer Research, vol. 50, no. 12, pp. 3743–3747, 1990. View at Scopus
63. K. Hasegawa, S. Ito, S. Inoue, K. Wakamatsu, H. Ozeki, and I. Ishiguro, “Dihydro-1,4-benzothiazine-6,7-dione, the ultimate toxic metabolite of 4-S-cysteaminylphenol and 4-S-cysteaminylcatechol,” Biochemical Pharmacology, vol. 53, no. 10, pp. 1435–1444, 1997. View at Publisher · View at Google Scholar · View at Scopus
64. F. S. Hodi, S. J. O'Day, D. F. McDermott et al., “Improved survival with ipilimumab in patients with metastatic melanoma,” The New England Journal of Medicine, vol. 363, no. 8, pp. 711–723, 2010. View at Publisher · View at Google Scholar · View at Scopus
65. D. J. Schwartzentruber, D. H. Lawson, J. M. Richards et al., “gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma,” The New England Journal of Medicine, vol. 364, no. 22, pp. 2119–2127, 2011. View at Publisher · View at Google Scholar
66. C. Robert, L. Thomas, I. Bondarenko et al., “Ipilimumab plus dacarbazine for previously untreated metastatic melanoma,” The New England Journal of Medicine, vol. 364, pp. 2517–2526, 2011.
67. P. B. Chapman, A. Hauschild, C. Robert et al., “Improved survival with vemurafenib in melanoma with BRAF V600E mutation,” The New England Journal of Medicine, vol. 364, no. 26, pp. 2507–2516, 2011. View at Publisher · View at Google Scholar
68. K. Mise, N. Kan, T. Okino et al., “Effect of heat treatment on tumor cells and antitumor effector cells,” Cancer Research, vol. 50, no. 19, pp. 6199–6202, 1990. View at Scopus
69. A. Ito, F. Matsuoka, H. Honda, and T. Kobayashi, “Heat shock protein 70 gene therapy combined with hyperthermia using magnetic nanoparticles,” Cancer Gene Therapy, vol. 10, no. 12, pp. 918–925, 2003. View at Publisher · View at Google Scholar · View at Scopus